Elizabeth A. Garofalo
CIK: 0001826361
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Jun 17, 2026ALEC
Alector, Inc.
Award(A)Direct28.7K shares- - Jun 3, 2026XENE
Xenon Pharmaceuticals Inc.
Award(A)DirectShare Option (Right to Buy)
10.5K shares- - Jun 3, 2026XENE
Xenon Pharmaceuticals Inc.
Award(A)DirectRestricted Share Units
1.6K shares- - Jun 1, 2026XENE
Xenon Pharmaceuticals Inc.
Exercise(M)Direct2.6K shares- - May 29, 2026ACAD
ACADIA PHARMACEUTICALS INC
Award(A)DirectDirector Stock Options (Right to Buy)
16K shares- - May 29, 2026ACAD
ACADIA PHARMACEUTICALS INC
Exercise(M)Direct8.1K shares- - May 29, 2026ACAD
ACADIA PHARMACEUTICALS INC
Award(A)DirectRestricted Stock Units
9.3K shares- - Sep 2, 2025ACAD
ACADIA PHARMACEUTICALS INC
Sale(S)Direct1.6K shares at avg. $25.98$42K - Jun 11, 2025ALEC
Alector, Inc.
Award(A)Direct28.7K shares- - Jun 5, 2025XENE
Xenon Pharmaceuticals Inc.
Award(A)DirectShare Option (Right to Buy)
17K shares- - Jun 5, 2025XENE
Xenon Pharmaceuticals Inc.
Award(A)DirectRestricted Share Units
2.6K shares- - May 29, 2025ACAD
ACADIA PHARMACEUTICALS INC
Exercise(M)Direct9.4K shares- - May 29, 2025ACAD
ACADIA PHARMACEUTICALS INC
Award(A)DirectDirector Stock Options (Right to Buy)
13.8K shares- - May 29, 2025ACAD
ACADIA PHARMACEUTICALS INC
Award(A)DirectRestricted Stock Units
8.1K shares- - Mar 5, 2025ACAD
ACADIA PHARMACEUTICALS INC
Sale(S)Direct4.9K shares at avg. $18.23$90K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 17, 2026 |  ALEC Alector, Inc. | Award(A) | 28,700 | - | $0 | Direct |
| Jun 3, 2026 |  XENE Xenon Pharmaceuticals Inc. | Award(A) Share Option (Right to Buy) | 10,507 | - | - | Direct |
| Jun 3, 2026 | XENE Xenon Pharmaceuticals Inc. | Award(A) Restricted Share Units | 1,593 | - | - | Direct |
| Jun 1, 2026 | XENE Xenon Pharmaceuticals Inc. | Exercise(M) | 2,645 | - | $0 | Direct |
| May 29, 2026 |  ACAD ACADIA PHARMACEUTICALS INC | Award(A) Director Stock Options (Right to Buy) | 16,004 | - | - | Direct |
| May 29, 2026 | ACAD ACADIA PHARMACEUTICALS INC | Exercise(M) | 8,107 | - | $0 | Direct |
| May 29, 2026 | ACAD ACADIA PHARMACEUTICALS INC | Award(A) Restricted Stock Units | 9,311 | - | - | Direct |
| Sep 2, 2025 | ACAD ACADIA PHARMACEUTICALS INC | Sale(S) | 1,600 | $25.98 | $41,560 | Direct |
| Jun 11, 2025 | ALEC Alector, Inc. | Award(A) | 28,700 | - | - | Direct |
| Jun 5, 2025 | XENE Xenon Pharmaceuticals Inc. | Award(A) Share Option (Right to Buy) | 17,012 | - | - | Direct |
| Jun 5, 2025 | XENE Xenon Pharmaceuticals Inc. | Award(A) Restricted Share Units | 2,645 | - | - | Direct |
| May 29, 2025 | ACAD ACADIA PHARMACEUTICALS INC | Exercise(M) | 9,387 | - | - | Direct |
| May 29, 2025 | ACAD ACADIA PHARMACEUTICALS INC | Award(A) Director Stock Options (Right to Buy) | 13,793 | - | - | Direct |
| May 29, 2025 | ACAD ACADIA PHARMACEUTICALS INC | Award(A) Restricted Stock Units | 8,107 | - | - | Direct |
| Mar 5, 2025 | ACAD ACADIA PHARMACEUTICALS INC | Sale(S) | 4,919 | $18.23 | $89,673 | Direct |
1-15 of 15 transactions
About GAROFALO ELIZABETH A.
GAROFALO ELIZABETH A. (SEC CIK 0001826361) files insider reports with the SEC as Director of Alector, Inc. (ALEC), Director of Xenon Pharmaceuticals Inc. (XENE) and Director of ACADIA PHARMACEUTICALS INC (ACAD).
Signal8 holds 8 ownership filings by GAROFALO ELIZABETH A., all Form 4s, filed between Mar 6, 2025 and Jun 17, 2026. Those filings report 15 transactions, from Mar 5, 2025 to Jun 17, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on GAROFALO ELIZABETH A.'s filings is in SAN DIEGO, CA.
Recent filings by GAROFALO ELIZABETH A.
- Jun 17, 2026: Grant or award of ALEC shares (Form 4, code A).
- Jun 3, 2026: Grants or awards of XENE derivative securities (2 lines, Form 4, code A).
- Jun 1, 2026: Option exercise of XENE shares (Form 4, code M).
- May 29, 2026: Grant or award of ACAD derivative securities (Form 4, code A).
- May 29, 2026: Option exercise of ACAD shares (Form 4, code M).
Other insiders filing for Alector, Inc. (ALEC)
- Rosenthal Arnon, Chief Executive Officer
- Wong-Sarad Grace, Principal Accounting Officer
- Berkley Neil Lindsay, CFO & Chief Business Officer
- Yaffe Kristine, Director
- SCHELLER RICHARD H, Director
- Hammond Paula, Director